[go: up one dir, main page]

WO1999034785A3 - Treatment of dyskinesias - Google Patents

Treatment of dyskinesias Download PDF

Info

Publication number
WO1999034785A3
WO1999034785A3 PCT/IL1999/000003 IL9900003W WO9934785A3 WO 1999034785 A3 WO1999034785 A3 WO 1999034785A3 IL 9900003 W IL9900003 W IL 9900003W WO 9934785 A3 WO9934785 A3 WO 9934785A3
Authority
WO
WIPO (PCT)
Prior art keywords
dyskinesias
treatment
dyskinesia
riluzole
levodopa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL1999/000003
Other languages
French (fr)
Other versions
WO1999034785A2 (en
Inventor
Eldad Melamed
Ruth Djaldetti
Ilan Ziv
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mor Research Applications Ltd
Original Assignee
Mor Research Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12288398A external-priority patent/IL122883A0/en
Priority claimed from IL12710298A external-priority patent/IL127102A0/en
Priority to IL13719099A priority Critical patent/IL137190A0/en
Priority to JP2000527236A priority patent/JP2002500181A/en
Priority to BR9906821-4A priority patent/BR9906821A/en
Priority to US09/582,989 priority patent/US6417210B1/en
Priority to CA002317811A priority patent/CA2317811A1/en
Priority to AU17806/99A priority patent/AU1780699A/en
Application filed by Mor Research Applications Ltd filed Critical Mor Research Applications Ltd
Priority to EP99900116A priority patent/EP1043996A2/en
Priority to PL99342098A priority patent/PL342098A1/en
Priority to KR1020007007567A priority patent/KR20010033978A/en
Publication of WO1999034785A2 publication Critical patent/WO1999034785A2/en
Publication of WO1999034785A3 publication Critical patent/WO1999034785A3/en
Priority to NO20003529A priority patent/NO20003529L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Levodopa-induced dyskinesia and tardative dyskinesia are ameliorated by administration of riluzole to needing subjects.
PCT/IL1999/000003 1998-01-09 1999-01-05 Treatment of dyskinesias Ceased WO1999034785A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL99342098A PL342098A1 (en) 1998-01-09 1999-01-05 Pharmacological compositions for treating diskineses
KR1020007007567A KR20010033978A (en) 1998-01-09 1999-01-05 Treatment of Dyskinesias
EP99900116A EP1043996A2 (en) 1998-01-09 1999-01-05 Treatment of dyskinesias
BR9906821-4A BR9906821A (en) 1998-01-09 1999-01-05 Pharmaceutical composition and process to improve levodopa-induced dyskinesia and tardive dyskinesia, and use of riluzole for the preparation of a pharmaceutical composition
US09/582,989 US6417210B1 (en) 1998-01-09 1999-01-05 Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
CA002317811A CA2317811A1 (en) 1998-01-09 1999-01-05 Treatment of dyskinesias
AU17806/99A AU1780699A (en) 1998-01-09 1999-01-05 Treatment of dyskinesias
IL13719099A IL137190A0 (en) 1998-01-09 1999-01-05 Pharmaceutical compositions for the treatment of dyskinesias
JP2000527236A JP2002500181A (en) 1998-01-09 1999-01-05 Dyskinesia treatment
NO20003529A NO20003529L (en) 1998-01-09 2000-07-07 Treatment of dyskinesia conditions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL12288398A IL122883A0 (en) 1998-01-09 1998-01-09 Pharmaceutical compositions for the treatment of dyskinesias
IL122883 1998-01-09
IL127102 1998-11-17
IL12710298A IL127102A0 (en) 1998-11-17 1998-11-17 Pharmaceutical compositions for the treatment of dyskinesias

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/899,639 Continuation US6669122B2 (en) 1999-01-11 2001-07-05 Method and apparatus for shaping particles by ultrasonic cavitation

Publications (2)

Publication Number Publication Date
WO1999034785A2 WO1999034785A2 (en) 1999-07-15
WO1999034785A3 true WO1999034785A3 (en) 1999-09-16

Family

ID=26323572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL1999/000003 Ceased WO1999034785A2 (en) 1998-01-09 1999-01-05 Treatment of dyskinesias

Country Status (10)

Country Link
EP (1) EP1043996A2 (en)
JP (1) JP2002500181A (en)
KR (1) KR20010033978A (en)
CN (1) CN1290166A (en)
AU (1) AU1780699A (en)
BR (1) BR9906821A (en)
CA (1) CA2317811A1 (en)
NO (1) NO20003529L (en)
PL (1) PL342098A1 (en)
WO (1) WO1999034785A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054772A1 (en) * 1999-03-12 2000-09-21 Aventis Pharma S.A. Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist
FR2790670A1 (en) * 1999-03-12 2000-09-15 Aventis Pharma Sa Treatment or prevention of amyotrophic lateral sclerosis, using synergistic combination of riluzole and AMPA receptor antagonist, e.g. 5H,10H-imidazo (1,2-a) indeno (1,2-e) pyrazin-4-one derivative
FR2801793B1 (en) * 1999-12-01 2003-07-04 Aventis Pharma Sa COMBINATION OF ERGOLIN AND RILUZOLE AND ITS USE AS A MEDICINAL PRODUCT
US6297254B1 (en) 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease
FR2809620B1 (en) * 2000-06-05 2002-08-02 Aventis Pharma Sa USE OF RILUZOLE OR ITS SALTS FOR THE PREVENTION AND TREATMENT OF ADRENOLEUCODYSTROPHY
EP1256340B1 (en) * 2001-05-08 2003-08-13 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0558861A1 (en) * 1992-03-06 1993-09-08 Aventis Pharma S.A. Use of amino-2-trifluoromethoxy-6-benzothiazole (riluzole) for the manufacture of a medicament for the treatment of motor neuron diseases
WO1994015601A1 (en) * 1993-01-07 1994-07-21 Rhone-Poulenc Rorer S.A. Application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0558861A1 (en) * 1992-03-06 1993-09-08 Aventis Pharma S.A. Use of amino-2-trifluoromethoxy-6-benzothiazole (riluzole) for the manufacture of a medicament for the treatment of motor neuron diseases
WO1994015601A1 (en) * 1993-01-07 1994-07-21 Rhone-Poulenc Rorer S.A. Application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"riluzole; rilutek", DRUGS FUTURE, vol. 21, no. 10, 1996, pages 1077 - 1078, XP002109884 *
A. BENAZZOUZ ET AL.: "Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study", EUR.J.PHARMACOL., vol. 284, no. 3, 1995, pages 299 - 307, XP000600898 *
A. DOBLE: "Excitatory amino acid receptors and neurodegeneration", THÉRAPIE, vol. 50, no. 4, 1995, pages 319 - 337, XP002109885 *
A. RICHTER ET AL.: "Prodystonic effects of riluzole in an animal model of idiopathic dystonia related to decreased total power in the red nucleus?", EUR. J. PHARMACOL., vol. 332, no. 2, 1997, pages 133 - 141, XP002109887 *
A.IMPERATO ET AL.: "RILUZOLE PREVENTS DYSKINESIAS IN PARKINSONIAN MARMOSETS, BEHAVIOR AND HISTOLOGY.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, pages 763, XP002109889 *
G.C.KIEL: "Schlüsselfunktion von Glutamat im Netzwerk neurodegenerativer Prozesse", NEUROL.REHABIL., vol. 4, no. 6, 1998, pages 326 - 327, XP002109888 *
J.-L-VIDALUC: "MPTP as a Molecular Paradigm for Neurodegeneration. A Review of its Connections with Relevant Molecules", CURR.MED.CHEM., vol. 3, no. 2, 1996, pages 117 - 138, XP002109892 *
M.S.STARR ET AL.: "Stimulation of Basal and L-DOPA-induced Motor Activity by Glutamate Antagonists in Animal Models of Parkinson's Disease", NEUROSCI. BIOBEHAV. REV., vol. 21, no. 4, 1997, pages 437 - 446, XP002094843 *
O.K. HASSANI: "CONTROLE DOPAMINERGIQUE DU NOYAU SUBTHALAMIQUE CHEZ LE RAT NORMAL ET CHEZ LE RAT MODELE DE LA MALADIE DE PARKINSON (RATS 6-OHDA)", DIALOG (R) FILE 144: PASCAL (C): ACCESSION NUMBER 13759700: THESIS, 1997, université de paris, XP002109891 *
O.RASCOL ET AL.: "Pharmacologie clinique des dyskinésies induites par la L-Dopa chez les malades parkinsoniens", THÉRAPIE, vol. 53, no. 1, February 1998 (1998-02-01), pages 43 - 48, XP002094840 *
P. BARNÉOUD ET AL.: "NEUROPROTECTIVE EFFECTS OF RILUZOLE ON A MODEL OF PARKINON'S DISEASE IN THE RAT", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 21, no. 1-3, 1995, pages 1256, XP002109883 *
P. BARNÉOUD ET AL.: "NEUROPROTECTIVE EFFECTS OF RILUZOLE ON A MODEL OF PARKINSON'S DISEASE IN THE RAT", NEUROSCIENCE, vol. 74, no. 4, October 1996 (1996-10-01), pages 971 - 983, XP002109882 *
S. PALFI ET AL.: "Riluzole Reduces Incidence of Abnormal Movements but Not Striatal Cell Death in a Primate Model of Progressive Striatal Degeneration", EXP.NEUROL., vol. 146, no. 1, July 1997 (1997-07-01), pages 135 - 141, XP002109886 *
S. PALFI: "Nouvelles Approches Therapeutiques Experimentales pour le Traitement des Deficits Moteurs et Cognitifs de la Maladie de Huntington", DIALOG(R) FILE 144: PASCAL (C): ACCESSION NUMBER 13608133: THESIS, 1997, UNIVERSITÉ DE PARIS, XP002109890 *

Also Published As

Publication number Publication date
BR9906821A (en) 2000-10-17
NO20003529L (en) 2000-09-08
KR20010033978A (en) 2001-04-25
PL342098A1 (en) 2001-05-21
WO1999034785A2 (en) 1999-07-15
CA2317811A1 (en) 1999-07-15
AU1780699A (en) 1999-07-26
EP1043996A2 (en) 2000-10-18
CN1290166A (en) 2001-04-04
JP2002500181A (en) 2002-01-08
NO20003529D0 (en) 2000-07-07

Similar Documents

Publication Publication Date Title
AU2003239393A1 (en) Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2000011968A8 (en) ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
WO2002034072A3 (en) Synergistic antioxidant combination of delta tocols and polyphenols
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
AU6564794A (en) Use of nona- and decapeptides in the preparation of a drug for the treatment of aids
EP1441685A4 (en) Anti-irritating rosacea treatment
AU2915900A (en) Pharmaceutic, dietetic and cosmetic compositions based on thioctic acid and cysteine
AU6549898A (en) Method for the broad based treatment of infections, especially infections of organs such as the skin and vagina
CA2392620A1 (en) Use of melatonin for the treatment of androgenetic and diffuse alopecia
AU2001286562A1 (en) Use of agaricus blazei murill to prevent or treat skin and other disorders
AU2463099A (en) Gabapentin and its derivatives for the treatment of muscular and skeletal pain
WO2003090712A3 (en) Compositions for treating hyperemia
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
EP1300084A3 (en) Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves
AU1773600A (en) Topical treatment of skin disease
IS6178A (en) A composition comprising a basic bacterial origin of sphingomyelinases for use as a nutritional preparation, dietary supplement or pharmaceutical product.
WO1999034785A3 (en) Treatment of dyskinesias
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
PT1390007E (en) Cosmetic composition based on zinc and copper sulphates and sucralphate
AU5634500A (en) Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis
PL348781A1 (en) Soya extract containing lipids, process for its production, and pharmaceutical and cosmetic composition
WO2000071140A3 (en) Methods and compositions for modulating immune response and for the treatment of inflammatory disease
WO2004050010A3 (en) Composition, especially a cosmetic composition, containing at least one alkyl para-hydroxybenzoate and at least one lipophilic amino acid derivative
WO2001043705A3 (en) Compositions containing a retinoid and a stilbene for skin care

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99802790.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2317811

Country of ref document: CA

Ref document number: 2317811

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 137190

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020007007567

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/006800

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999900116

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 17806/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09582989

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999900116

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007007567

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020007007567

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999900116

Country of ref document: EP